Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Journal:

Journal of Clinical Oncology

Published:

2025-10-03

DOI:

10.1200/jco-25-01957

Affiliations:

21

Authors:

86

Go to article

Institutions	Authors	Share
Genentech, Inc., United States of America (USA)	9.000000	0.32
Samsung Medical Center (SMC), South Korea	1.000000	0.04
Hospital de Clínicas de Porto Alegre (HCPA), UFRGS, Brazil	1.000000	0.04
Beneficência Portuguesa de São Paul, Brazil	1.000000	0.04
Chiang Mai University (CMU), Thailand	1.000000	0.04
Hoffmann-La Roche Ltd., Canada	1.000000	0.04
Tianjin Medical University Cancer Institute and Hospital, TMU, China	1.000000	0.04
Ankara University, Turkey	1.000000	0.04
City of Hope, United States of America (USA)	1.000000	0.04
Fundaleu, Argentina	1.000000	0.04
Cancer Institute Hospital, JFCR, Japan	1.000000	0.04
Brown University, United States of America (USA)	1.000000	0.04
Tampa General Hospital (TGH), United States of America (USA)	1.000000	0.04
D'Or Institute for Research and Education (IDOR), Brazil	1.000000	0.04
Hokkaido University Hospital, Japan	1.000000	0.04
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.04
Yeouido St. Mary's Hospital, South Korea	1.000000	0.04
F. Hoffmann-La Roche Ltd., Switzerland	1.000000	0.04
Sichuan Cancer Hospital, China	1.000000	0.04
Levine Cancer Institute, Atrium Health, United States of America (USA)	1.000000	0.04

Interested in Cardiovascular Medicine and Haematology?